SMARCA1 and neoplasm: These inhibitors partially complement the histone acetylation function of the SWI/SNF complex in SMARCB1-deficient MRTs, enhancing the expression of differentiation markers and inhibiting the proliferation signaling of tumor cells (191, 192).